Torrent Pharma Q2 FY26 PAT up 30% YoY at Rs 591 cr
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts more than Nifty 100 and 6.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Torrent Pharma reported Q2 FY26 consolidated revenue of Rs 3,302 cr, up 14% YoY. Operating EBITDA rose 15% to Rs 1,083 cr with margin at 32.8%. Net profit jumped 30% YoY to Rs 591 cr, driven by strong branded business. H1 FY26 PAT grew 25% to Rs 1,139 cr. Exceptional item of Rs 13 cr relates to JB Pharma acquisition fees. CCI approval received on Oct 21 and SEBI observation on draft letter of offer received on Oct 30, 2025 for the proposed JB Pharma deal worth about Rs 11,917 cr.
Strong earnings driven by branded business; progress on JB Pharma acquisition with key regulatory approvals supports future growth outlook.